Retnakaran Ravi, Youn Byung-Soo, Liu Ying, Hanley Anthony J G, Lee Nam Seok, Park Ji Woo, Song Eun Sun, Vu Vivian, Kim Wi, Tungtrongchitr Rungsunn, Havel Peter J, Swarbrick Michael M, Shaw Collin, Sweeney Gary
Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, ON, Canada.
Clin Endocrinol (Oxf). 2008 Dec;69(6):885-93. doi: 10.1111/j.1365-2265.2008.03264.x. Epub 2008 Apr 10.
Here we use a novel ELISA that is specific for full-length visfatin (PBEF/NAMPT), compare it with the existing C-terminal based assay and use it to investigate associations of visfatin with metabolic parameters.
DESIGN, PATIENTS AND MEASUREMENTS: We established the specificity and effectiveness of the new ELISA and evaluated the associations of full-length visfatin with clinical, anthropometric and metabolic parameters in a cross-sectional study of 129 Thai subjects, consisting of 50 outpatients with type 2 diabetes and 79 healthy volunteers.
The new ELISA accurately recovered full-length recombinant visfatin and detected visfatin secreted by primary human and rat adipocytes. We found serum full-length visfatin was significantly higher in subjects with diabetes compared to their nondiabetic peers (median 2.75 vs. 2.22 ng/ml, P = 0.0142). After adjustment for age, gender and traditional metabolic risk factors, adjusted mean visfatin remained significantly higher in the diabetes group (3.80 vs. 2.10 ng/ml, P = 0.0021). On Spearman univariate correlation analysis, visfatin was significantly associated with resistin (r = 0.30, P = 0.0011), but not with any other anthropometric or metabolic variables, including adiponectin multimers. On multiple linear regression analysis, the only covariates independently associated with visfatin were diabetes (t = 3.11, P = 0.0024) and log resistin (t = 2.68, P = 0.0086).
Circulating visfatin is independently associated with diabetes and resistin concentration, but is not related to adiponectin multimers or other metabolic covariates. These data are suggestive of a potential role of visfatin in subclinical inflammatory states.
在此我们使用一种针对全长内脂素（PBEF/NAMPT）的新型酶联免疫吸附测定法（ELISA），将其与现有的基于C端的检测方法进行比较，并使用它来研究内脂素与代谢参数之间的关联。
设计、研究对象与测量方法：我们确立了新型ELISA的特异性和有效性，并在一项对129名泰国受试者的横断面研究中评估了全长内脂素与临床、人体测量学和代谢参数之间的关联，这些受试者包括50名2型糖尿病门诊患者和79名健康志愿者。
新型ELISA准确地回收了全长重组内脂素，并检测到原代人脂肪细胞和大鼠脂肪细胞分泌的内脂素。我们发现，与非糖尿病同龄人相比，糖尿病患者的血清全长内脂素显著更高（中位数分别为2.75与2.22 ng/ml，P = 0.0142）。在对年龄、性别和传统代谢危险因素进行校正后，糖尿病组校正后的内脂素平均水平仍然显著更高（3.80与2.10 ng/ml，P = 0.0021）。在Spearman单变量相关性分析中，内脂素与抵抗素显著相关（r = 0.30，P = 0.0011），但与任何其他人体测量学或代谢变量均无关联，包括脂联素多聚体。在多元线性回归分析中，与内脂素独立相关的唯一协变量是糖尿病（t = 3.11，P = 0.0024）和抵抗素对数（t = 2.68，P = 0.0086）。
循环内脂素与糖尿病和抵抗素浓度独立相关，但与脂联素多聚体或其他代谢协变量无关。这些数据提示内脂素在亚临床炎症状态中可能发挥作用。
